Initiates Coverage on Moleculin Biotech (NASDAQ:MBRX)

Research analysts at assumed coverage on shares of Moleculin Biotech (NASDAQ:MBRXGet Free Report) in a report issued on Saturday. The firm set a “sell” rating on the stock.

Other analysts also recently issued reports about the stock. Roth Mkm reaffirmed a “buy” rating and set a $40.00 price objective on shares of Moleculin Biotech in a report on Friday, April 12th. Maxim Group dropped their price target on Moleculin Biotech from $45.00 to $20.00 and set a “buy” rating for the company in a research note on Tuesday, March 26th.

Get Our Latest Analysis on MBRX

Moleculin Biotech Trading Down 1.1 %

Shares of MBRX opened at $3.74 on Friday. Moleculin Biotech has a 12-month low of $3.52 and a 12-month high of $15.75. The stock has a 50-day moving average price of $4.61 and a 200-day moving average price of $7.05.

Moleculin Biotech (NASDAQ:MBRXGet Free Report) last announced its earnings results on Friday, May 10th. The company reported ($2.02) earnings per share for the quarter, beating analysts’ consensus estimates of ($3.59) by $1.57. As a group, research analysts expect that Moleculin Biotech will post -8.79 earnings per share for the current year.

Hedge Funds Weigh In On Moleculin Biotech

A hedge fund recently bought a new stake in Moleculin Biotech stock. Atticus Wealth Management LLC acquired a new stake in shares of Moleculin Biotech, Inc. (NASDAQ:MBRXFree Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 50,001 shares of the company’s stock, valued at approximately $43,000. Atticus Wealth Management LLC owned 0.17% of Moleculin Biotech as of its most recent filing with the Securities and Exchange Commission (SEC). 15.52% of the stock is owned by hedge funds and other institutional investors.

About Moleculin Biotech

(Get Free Report)

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.

Read More

Receive News & Ratings for Moleculin Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moleculin Biotech and related companies with's FREE daily email newsletter.